eXoZymes Inc (EXOZ) FinancialsEXOZeXoZymes Inc

Evaluating the bottom line, eXoZymes Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -187.16%, provide a clear picture of how effectively EXOZ converts its operational activities into shareholder value.

In the context of the broader market, EXOZ competes directly with industry leaders such as UG and HTOO. With a market capitalization of $40.92M, it holds a leading position in the sector. When comparing efficiency, EXOZ's gross margin of N/A stands against UG's 49.73% and HTOO's 12.36%. Such benchmarking helps identify whether eXoZymes Inc is trading at a premium or discount relative to its financial performance.

Exozymes has reported consistent net losses, with the latest net income at -2,878,614 USD for Q2 2026. The gross profit has been negative in several quarters, indicating challenges in profitability. The forward P/E ratio is 0, suggesting the company is not expected to generate earnings in the near term.